The Effect of Practolol,In Vitro Generated Metabolites of Practolol and Chemical Analogues on the Rate of Growth of Human Skin Fibroblasts

Abstract

The rate of growth of normal human skin fibroblasts was inhibited in a dose related, reversible, fashion by practolol (N-4-(2-hydroxy)-3 (1-methyl)-aminopropoxyphenylacetamine) (ID₅₀ 1.35 ± 0.14 x 10^-3M), propranolol (1-(isopropylamino)-3(1-naphthyl-oxy)-2-propranolol) (ID₅₀ 0.145 ± 0.02 x 10^-3M) and paracetamol (N-(4-hydroxyphenyl) acetamide) (ID₅₀ 0.85 ± 0.2 x 10^-3M). Skin fibroblasts isolated from a psoriasis patient were more sensitive towards practolol (ID₅₀ 0.48 ± 0.14 x 10^-3M) and propranolol (ID₅₀ 0.032 ± 0.002 x 10^-3M), but less sensitive towards paracetamol (ID₅₀ 1.3 ± 0.07 x 10^-3M). In vitro generated metabolites of practolol, using normal or Arochlor 1254-pretreated hamster liver preparations, and structural analogues of practolol had no effect upon the growth of either cell type.

Keywords

practolol practolol metabolites analogues of practolol propranolol paracetamol human skin fibroblast growth

Get full access to this article

View all access options for this article.

References

Cruickshank

J.J.

(1983). How safe are β-blockers? Drugs 25, 331–340.

Wright

(1975). Untoward effects associated with practolol administration: oculomucocutaneous syndrome. British Medical Journal 1, 595–598.

Felix

R.H.

, Ive

F.A.

, and Dahl

M.G.C.

(1974). Cutaneous and ocular reactions to practolol. British Medical Journal 4, 321–324.

Brown

, Baddeley

, Read

A.E.

, Davies

J.D.

, and McGarry

(1974). Sclerosing peritonitis, an unusual reaction to a β-adrenergic blocking drug (practolol). Lancet i, 1477–1481.

Case

D.E.

, Lindup

W.E.

, Lowery

, Orton

T.C.

, Reeves

P.R.

, and Whittaker

S.E.

(1978). Metabolism studies with practolol. British Journal of Parmacology 63, 352P.

Nicholls

R.T.

(1976). Adverse effects of practolol. Annals of Clinical Research 8, 229–231.

Reeves

P.R.

, Case

D.E.

, Jepson

H.T.

, McCormick

D.J.

, Nicholls

R.T.

, Felix

R.H.

, Holt

P.J.L.

, Zacharias

F.J.

, and Fluke

R.W.

(1978). Practolol metabolism. II. Metabolism in human subjects. Journal of Pharmacology and Experimental Therapeutics 205, 489–498.

Amos

H.E.

, Lake

B.G.

, and Atkinson

H.A.C.

(1977). Allergic drug reactions: an in vitro model using a mixed function oxidase complex to demonstrate antibodies with specificity for a practolol metabolite. Clinical Allergy 7, 423–428.

Amos

H.E.

, Lake

B.G.

, and Artis

(1978). Possible role of antibodies specific for a practolol metabolite in the pathogenesis of oculomucocutaneous syndrome. British Medical Journal 1, 402–404.

10.

Shafer

W.G.

(1960). Effect of dilantin sodium on growth of human fibroblast-like cell cultures. Proceedings of the Society for Experimental Biology and Medicine 104, 198–201.

11.

Shafer

W.G.

(1961). Effect of dilantin sodium analogues on cell proliferation in tissue culture. Proceedings of the Society for Experimental Biology and Medicine 106, 205–207.

12.

Lindup

W.E.

, Longshaw

, Orton

T.C.

, and Whittaker

S.E.

(1979). The distribution and irreversible tissue binding of practolol and its metabolites in the hamster. British Journal of Pharmacology 66, 504P.

13.

Fitzgerald

J.D.

, and Scales

(1968). Effect of a new adrenergic beta-blocking agent (ICI 50, 172) on heart rate in relation to its blood levels. International Journal of Clinical Pharmacology 1, 467–474.

14.

Bodem

, and Chidsey

C.A.

(1973). Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man. Clinical Pharmacology and Therapeutics 14, 26–29.

15.

Scales

, and Cosgrove

M.B.

(1970). The metabolism and distribution of the selective adrenergic beta-blocking agent, practolol. Journal of Pharmacology and Experimental Therapeutics 175, 335–347.

16.

Tanaka

, Ohkawa

, Hiama

, and Nakajima

(1983). Evaluation of ocular toxicity of two beta-blocking drugs, carteolol and practolol, in Beagle dogs. Journal of Pharmacology and Experimental Therapeutics 224, 424–430.

17.

Okine

L.K.

, Ionnides

, and Parke

D.V.

(1983). Inhibition of gastrointestinal mucosal glycoprotein synthesis by the beta-adrenergic blocking drug, practolol. Biochemical Pharmacology 31, 2263–2266.